Lakefront Biotherapeutics (GLPGF) Non Operating Interest Expenses (2016 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Non Operating Interest Expenses for 11 consecutive years, with -$160392.2 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Non Operating Interest Expenses rose 80.45% year-over-year to -$160392.2 in Q1 2026; TTM through Mar 2026 was -$3.3 billion, a 86.65% decrease from a year earlier, with the FY2025 full-year figure at -$3.2 billion, down 78.96% from the prior year.
• Non Operating Interest Expenses was -$160392.2 for Q1 2026 at Lakefront Biotherapeutics, up from -$3.3 billion in the prior quarter.
• Over five years, Non Operating Interest Expenses peaked at $260606.8 in Q2 2024 and troughed at -$10.0 billion in Q4 2022.
• A 5-year average of -$1.4 billion and a median of -$880772.0 in 2024 frame the typical range for Non Operating Interest Expenses.
• Across the five-year window, Non Operating Interest Expenses soared 80.81% in 2023 and sank 353.66% in 2025, its largest moves.
• Over 5 years, Non Operating Interest Expenses stood at -$10.0 billion in 2022, then soared by 72.01% to -$2.8 billion in 2023, then jumped by 36.53% to -$1.8 billion in 2024, then tumbled by 86.71% to -$3.3 billion in 2025, then soared by 100.0% to -$160392.2 in 2026.
• The last three Non Operating Interest Expenses figures came in at -$160392.2 (Q1 2026), -$3.3 billion (Q4 2025), and -$777421.6 (Q3 2025), per Business Quant data.